Detail page

Knowledge Web

Person

Andreas Hochhaus (1959-)

Arzt

Name	Andreas Hochhaus
Time	1959- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Jena (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med. (an der Medizinischen Fakultät der Universität Heidelberg)(apl. Prof.) (2003)
Profession	Arzt (characteristic profession)
Variant	A. Hochhaus
Related	Universitätsklinikum Jena Klinik für Innere Medizin II (Jena) (2010-) Universitätsklinikum Jena. Institut für Infektionsmedizin und Krankenhaushygiene Friedrich-Schiller-Universität Jena. Institut für Mikrobiologie Universitätsklinikum Mannheim (III. Medizinische Klinik) (1990-1997, 2007-2009) Universität Heidelberg. Medizinische Fakultät Mannheim
Further information	José-Carreras-Stiftungsprofessur für Leukämieforschung an der Universität Heidelberg und führte kommissarisch die III. Medizinische Klinik der Universitätsmedizin in Mannheim; Professur für Allgemeine Innere Medizin mit Schwerpunkt Hämatologie und Onkologie an der Friedrich-Schiller-Universität
Source	Homepage: https://www.uniklinikum-jena.de/kim2/H%C3%A4matologie+und+Internistische+Onkologie/Unsere+Mitarbeiter/Leitung/Weiterf%C3%BChrende+Informationen+zu+Prof_+Hochhaus-p-3654.html (Stand: 09.12.2022)
Record type	Person
GND-Identifier	1107039339
Record ID	1107039339
Involved in show all Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5 FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN) In-ovo Bildgebung an Straußeneiern : Evaluierung einer Alternative zum klassischen Tierversuch Venous and Arterial Thromboembolism in Lung Cancer Patients : A Retrospective Analysis Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Survival with chronic myeloid leukaemia after failing milestones Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia Pomalidomide combinations are a safe and effective option after daratumumab failure Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study Chronische myeloische Leukämie Einzelzellanalyse an Tumorzellen des Lungenkarzinoms Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution Pomalidomide combinations are a safe and effective option after daratumumab failure Pomalidomide combinations are a safe and effective option after daratumumab failure Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Therapie der chronischen myeloischen Leukämie mit dem allosterischen BCR::ABL1-Inhibitor Asciminib Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Impact of emerging ACA on survival in chronic myeloid leukemia (CML) ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials Chronische myeloische Leukämie : Ratgeber für Patienten Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry Nuklearmedizinische Kontrolle der Nierenfunktion im Langzeitverlauf nach peptidvermittelter Radiorezeptortherapie neuroendokriner Tumore : Auswertung der Nierenfunktionsparameter von Patienten mit einem neuroendokrinen Tumor, die von 2001 bis 2008 in der Klinik für Molekulare Radiotherapie der Zentralklinik Bad Berka behandelt wurden Phosphorylation-dependent differences in CXCR4-LASP1-AKT1 Interaction between breast cancer and chronic myeloid leukemia Chronische Myeloische Leukämie Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV Chronische myeloische Leukämie Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Chronische Myeloische Leukämie Aktive Immuntherapie bei gastrointestinalen Tumoren : eine in vitro und in vivo Analyse Calcium dysregulation in mononuclear cells from patients with Amyotrophic lateral sclerosis

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Andreas Hochhaus (1959-)

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis

Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms – a practical guide to WHO-HAEM5

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

In-ovo Bildgebung an Straußeneiern : Evaluierung einer Alternative zum klassischen Tierversuch

Venous and Arterial Thromboembolism in Lung Cancer Patients : A Retrospective Analysis

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Survival with chronic myeloid leukaemia after failing milestones

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia

Pomalidomide combinations are a safe and effective option after daratumumab failure

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Chronische myeloische Leukämie

Einzelzellanalyse an Tumorzellen des Lungenkarzinoms

Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution

Pomalidomide combinations are a safe and effective option after daratumumab failure

Pomalidomide combinations are a safe and effective option after daratumumab failure

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Therapie der chronischen myeloischen Leukämie mit dem allosterischen BCR::ABL1-Inhibitor Asciminib

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera : futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Chronische myeloische Leukämie : Ratgeber für Patienten

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry

Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry

Phosphorylation-dependent differences in CXCR4-LASP1-AKT1 Interaction between breast cancer and chronic myeloid leukemia

Chronische Myeloische Leukämie

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Chronische myeloische Leukämie

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

Chronische Myeloische Leukämie

Aktive Immuntherapie bei gastrointestinalen Tumoren : eine in vitro und in vivo Analyse

Calcium dysregulation in mononuclear cells from patients with Amyotrophic lateral sclerosis